# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-26-191532
Filing Date
2026-04-29
Accepted
2026-04-29 16:08:12
Documents
17
Period of Report
2026-06-09

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | prld-20260429.htm iXBRL | DEF 14A | 981654
2 | GRAPHIC | img124090035_0.gif | GRAPHIC | 7345
3 | GRAPHIC | img124090035_1.gif | GRAPHIC | 178041
4 | GRAPHIC | img124090035_2.gif | GRAPHIC | 172250
5 | GRAPHIC | img124090035_3.jpg | GRAPHIC | 341021
6 | GRAPHIC | img124090035_4.jpg | GRAPHIC | 392348
| Complete submission text file | 0001193125-26-191532.txt |  | 4876903

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
7 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | prld-20260429.xsd | EX-101.SCH | 15022
20 | EXTRACTED XBRL INSTANCE DOCUMENT | prld-20260429_htm.xml | XML | 355847

Mailing Address 175 INNOVATION BOULEVARD WILMINGTON DE 19805
Business Address 175 INNOVATION BOULEVARD WILMINGTON DE 19805 (302) 467-1280
Prelude Therapeutics Inc (Filer) CIK: 0001678660 (see all company filings)

EIN.: 811384762 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39527 | Film No.: 26915998
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)